As IL-17-targeting monoclonal antibodies are effective as systemic psoriasis therapy for patients with moderate to severe psoriasis [19,20], our findings suggest that topical MTH1 inhibition could serve as a potentially effective local treatment by reducing IL-17 levels in the skin. Here, NUDT1 is linked to psoriasis.